• Ipsen completed its acquisition of Kartos Therapeutics, adding late-stage oncology asset navtemadlin to its pipeline.
• Navtemadlin is an oral MDM2 inhibitor in Phase III development for myelofibrosis as an add-on to ruxolitinib.
• The Phase III POIESIS study is testing navtemadlin plus ruxolitinib against ruxolitinib alone in patients with suboptimal response.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608210100PRIMZONEFULLFEED1001258581) on August 21, 2026, and is solely responsible for the information contained therein.